A number of firms have modified their ratings and price targets on shares of Jazz Pharmaceuticals plc – (NASDAQ: JAZZ) recently:

  • 4/8/2017 – Jazz Pharmaceuticals plc – was given a new $181.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 4/7/2017 – Jazz Pharmaceuticals plc – had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $190.00 price target on the stock.
  • 4/7/2017 – Jazz Pharmaceuticals plc – had its price target raised by analysts at Cantor Fitzgerald from $189.00 to $197.00. They now have an “overweight” rating on the stock.
  • 4/6/2017 – Jazz Pharmaceuticals plc – was downgraded by analysts at Mizuho from a “buy” rating to a “neutral” rating. They now have a $150.00 price target on the stock, down previously from $162.00.
  • 4/6/2017 – Jazz Pharmaceuticals plc – was upgraded by analysts at Janney Montgomery Scott from a “neutral” rating to a “buy” rating. They now have a $175.00 price target on the stock, up previously from $138.00.
  • 4/6/2017 – Jazz Pharmaceuticals plc – was downgraded by analysts at Vetr from a “strong-buy” rating to a “hold” rating. They now have a $157.46 price target on the stock.
  • 4/6/2017 – Jazz Pharmaceuticals plc – was given a new $170.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock.
  • 4/6/2017 – Jazz Pharmaceuticals plc – was given a new $176.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 4/3/2017 – Jazz Pharmaceuticals plc – was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $161.19 price target on the stock.
  • 3/28/2017 – Jazz Pharmaceuticals plc – was upgraded by analysts at TheStreet from a “c+” rating to a “b-” rating.
  • 3/27/2017 – Jazz Pharmaceuticals plc – was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $161.19 price target on the stock.
  • 3/21/2017 – Jazz Pharmaceuticals plc – had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $162.00 price target on the stock, up previously from $152.00.
  • 3/20/2017 – Jazz Pharmaceuticals plc – had its “positive” rating reaffirmed by analysts at BMO Capital Markets. They now have a $192.00 price target on the stock.
  • 3/20/2017 – Jazz Pharmaceuticals plc – had its “positive” rating reaffirmed by analysts at Cowen and Company. They now have a $190.00 price target on the stock.
  • 3/20/2017 – Jazz Pharmaceuticals plc – had its “outperform” rating reaffirmed by analysts at Leerink Swann.
  • 3/20/2017 – Jazz Pharmaceuticals plc – was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $161.19 price target on the stock.
  • 3/6/2017 – Jazz Pharmaceuticals plc – was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $151.20 price target on the stock.
  • 3/2/2017 – Jazz Pharmaceuticals plc – was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Jazz’s fourth-quarter earnings surpassed expectations, whereas revenues missed the same. Its sleep disorder drug, Xyrem, is the only FDA-approved product for both cataplexy and EDS. However, Xyrem is facing patent challenges. Jazz has also been facing challenges in building sufficient inventory levels for Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions in 2017. Jazz has also had its share of pipeline setbacks. On the other hand, its lead pipeline candidate, JZP-110 (being developed for the treatment of EDS in patients suffering from narcolepsy and OSA) complements its existing sleep disorder portfolio. In October, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos, and plans to finish it in early 2017. Jazz’ shares outperformed the industry so far this year.”
  • 3/1/2017 – Jazz Pharmaceuticals plc – had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $152.00 price target on the stock.
  • 3/1/2017 – Jazz Pharmaceuticals plc – had its price target lowered by analysts at Stifel Nicolaus from $200.00 to $190.00. They now have a “buy” rating on the stock.
  • 3/1/2017 – Jazz Pharmaceuticals plc – was given a new $170.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock.
  • 3/1/2017 – Jazz Pharmaceuticals plc – was given a new $187.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 2/28/2017 – Jazz Pharmaceuticals plc – was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $151.20 price target on the stock.
  • 2/22/2017 – Jazz Pharmaceuticals plc – is now covered by analysts at Evercore ISI. They set a “buy” rating and a $160.00 price target on the stock.
  • 2/22/2017 – Jazz Pharmaceuticals plc – was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $147.48 price target on the stock.
  • 2/21/2017 – Jazz Pharmaceuticals plc – had its price target raised by analysts at Mizuho from $127.00 to $152.00. They now have a “buy” rating on the stock.
  • 2/21/2017 – Jazz Pharmaceuticals plc – was downgraded by analysts at Vetr from a “strong-buy” rating to a “hold” rating. They now have a $141.22 price target on the stock.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded down 0.89% during midday trading on Friday, reaching $152.84. The company’s stock had a trading volume of 436,725 shares. The firm has a 50 day moving average price of $143.48 and a 200 day moving average price of $123.54. The firm has a market cap of $9.13 billion, a P/E ratio of 23.84 and a beta of 1.22. Jazz Pharmaceuticals plc – has a one year low of $95.80 and a one year high of $160.00.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, February 28th. The specialty pharmaceutical company reported $1.91 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.65 by $0.74. Jazz Pharmaceuticals plc – had a return on equity of 30.50% and a net margin of 24.81%. The firm earned $396.62 million during the quarter, compared to analysts’ expectations of $398.91 million. During the same period last year, the company earned $2.60 earnings per share. The business’s revenue for the quarter was up 16.4% compared to the same quarter last year. Equities research analysts forecast that Jazz Pharmaceuticals plc – will post $11.10 EPS for the current fiscal year.

In related news, SVP Paul Treacy sold 884 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $131.97, for a total value of $116,661.48. Following the sale, the senior vice president now directly owns 18,108 shares of the company’s stock, valued at approximately $2,389,712.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Karen J. Wilson sold 11,458 shares of the stock in a transaction dated Monday, April 10th. The stock was sold at an average price of $152.24, for a total transaction of $1,744,365.92. Following the completion of the sale, the senior vice president now directly owns 27,158 shares in the company, valued at $4,134,533.92. The disclosure for this sale can be found here. Insiders sold a total of 13,942 shares of company stock worth $2,098,147 over the last three months. 3.90% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with MarketBeat.com's FREE daily email newsletter.